Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
522 results about "Quinazolinone" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Quinazolinone is a heterocyclic chemical compound, a quinazoline with a keto group. There are two structural isomers, 2-quinazolinone and 4-quinazolinone, with the 4-isomer being the more common.
Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta
ActiveUS7932260B2Inhibit growth and proliferationInhibit growthBiocideSenses disorderLeukocyte functionWhite blood cell
Owner:ICOS CORP
5-Substituted quinazolinone derivatives and compositions comprising and methods of using the same
Provided are 5-substituted quinazolinone compounds, for example, of formula (I), and pharmaceutically acceptable salts, solvates, clathrates, stereoisomers, and prodrugs thereof. Methods of use for treating angiogenesis or cytokine related disorders, and pharmaceutical compositions of these compounds are disclosed.
Owner:CELGENE CORP
Methods and compositions utilizing quinazolinones
Owner:CYTOKINETICS INC
Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta
InactiveUS20100256167A1Inhibit growth and proliferationInhibit growthAntibacterial agentsBiocideDiseaseLeukocyte function
Compounds that inhibit PI3Kδ activity, including compounds that selectively inhibit PI3Kδ activity, are disclosed. Methods of inhibiting phosphatidylinositol 3-kinase delta isoform (PI3Kδ) activity, and methods of treating diseases, such as disorders of immunity and inflammation in which PI3Kδ plays a role in leukocyte function, using the compounds also are disclosed.
Owner:ICOS CORP
Quinazolinones as Inhibitors of Human Phosphatidylinositol 3-Kinase Delta
ActiveUS20080275067A1Inhibit growthPrevent proliferationBiocideSenses disorderDiseaseLeukocyte function
Compounds that inhibit PI3Kδ activity, including compounds that selectively inhibit PI3Kδ activity, are disclosed. Methods of inhibiting phosphatidylinositol 3-kinase delta isoform (PI3Kδ) activity, and methods of treating diseases, such as disorders of immunity and inflammation in which PI3Kδ plays a role in leukocyte function, using the compounds also are disclosed.
Owner:ICOS CORP
Quinazolinone containing pharmaceutical compositions for prevention of neovascularization and for treating malignancies
InactiveUS6028075AInhibit angiogenesisInhibit cell proliferationBiocideNervous disorderHydrogenNeovascularization
The invention provides a composition for attenuating neovascularization and treating malignancies, including a pharmaceutically effective amount of a compound having a formula: wherein: R1 is a member of the group consisting of hydrogen, halogen, nitro, benzo, lower alkyl, phenyl and lower alkoxy; R2 is a member of the group consisting of hydroxy, acetoxy, and lower alkoxy, and R3 is a member of the group consisting of hydrogen and lower alkenoxy carbonyl; as active ingredient therein, in combination with a pharmaceutically acceptable carrier.
Owner:HADASIT MEDICAL RES SERVICES & DEVMENT +1
Methods and compositions utilizing quinazolinones
Quinazolinones of formulae 1a, 1b, 1c and 1d are disclosed. They are useful for treating cellular proliferative diseases and disorders associated with KSP kinesin activity.
Owner:CYTOKINETICS INC
Syntheses of quinazolinones
The present invention provides novel quinazolinone compositions of matter comprising enantiomerically pure compound represented by Formula I:or a pharmaceutically acceptable salt thereof, having a detectable amount of one or more starting material and / or reagent used in the synthesis thereof.
Owner:CYTOKINETICS INC
Syntheses of quinazolinones
Owner:CYTOKINETICS INC
Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta
ActiveUS20100256168A1Inhibit growth and proliferationInhibit growthAntibacterial agentsBiocideDiseaseLeukocyte function
Compounds that inhibit PI3Kδ activity, including compounds that selectively inhibit PI3Kδ activity, are disclosed. Methods of inhibiting phosphatidylinositol 3-kinase delta isoform (PI3Kδ) activity, and methods of treating diseases, such as disorders of immunity and inflammation in which PI3Kδ plays a role in leukocyte function, using the compounds also are disclosed.
Owner:ICOS CORP
Substituted 2-alkyl quinazolinone derivatives as PARP inhibitors
Owner:JANSSEN PHARMA NV
Methods and compositions utilizing quinazolinones
Quinazolinones of formulae 1a, 1b, 1c and 1d are disclosed. They are useful for treating cellular proliferative diseases and disorders associated with KSP kinesin activity
Owner:CYTOKINETICS INC
Quinazolinone Compounds and Methods of Use Thereof
The present invention relates to quinazolinone compounds, and methods of preparation of these compounds. The present invention also relates to pharmaceutical compositions comprising the quinazolinone compounds. The present invention provides methods of treating a cell proliferative disorder, such as a cancer, by administering to a subject in need thereof a therapeutically effective amount of a quinazolinone compound of the present invention
Owner:ARQULE INC
Synthesis of quinazoline ketone compounds
InactiveCN101429165AReduce dosageHigh reaction yieldOrganic chemistryChemical recyclingOrganic solventKetone
The invention provides a synthetic method for a quinazolinone compound. The structure of the quinazolinone compound is shown as formula (I). The method comprises the following steps: using o-amino benzamide compound shown in structural formula (II) and aldehyde shown in structural formula (III) as raw materials, using trifluoro mesylate as a catalyst, making the mixture reacted for 10 minutes to 24 hours in an inert organic solvent at a temperature of between 25 and 200 DEG C, and separating and purifying the reaction liquor after the reaction is finished to obtain the quinazolinone compound. The method has the advantages of high reaction yield up to more than 85 percent generally, advanced and reasonable process routes, mild reaction conditions, little dosage of the catalyst, reutilization, and substantially no three wastes.
Owner:WENZHOU UNIVERSITY
5-Substituted quinazolinone derivatives and compositions comprising and methods of using the same
Provided are 5-substituted quinazolinone compounds, and pharmaceutically acceptable salts, solvates, clathrates, stereoisomers, and prodrugs thereof. Methods of use, and pharmaceutical compositions of these compounds are disclosed.
Owner:CELGENE CORP
Methods of treating hematological disorders with quinazolinone compounds in selected subjects
This disclosure relates to methods of selecting a subset of subjects having a hematological disorder and treating the selected group with a PI3K-delta inhibitor. In particular, the methods disclose evaluating levels of characteristic chemokine biomarkers, such as CCL2, CCL3, CCL4, CCL5, CXCL13, CCL17, CCL22, or TNF-alpha to select subjects that would have a greater chance of benefiting from treatment with a PI3K-delta inhibitor. The PI3K-delta inhibitors disclosed in this application are a type of quinazolinone-purinyl family of compounds.
Owner:GILEAD CALISTOGA
Quinazolinone-based oncogenic-ras-selective lethal compounds and their use
The present invention provides, inter alia, compounds having the structure (1) compositions containing such compounds are also provided. Methods for using such compounds or compositions for treating or ameliorating the effects of a cancer having a cell that harbors an oncogenic RAS mutation, for modulating a lipoxygenase in a ferroptosis cell death pathway, and for depleting reduced glutathione (GSH) in a cell harboring an oncogenic RAS mutation are further provided.
Owner:THE TRUSTEES OF COLUMBIA UNIV IN THE CITY OF NEW YORK
Quinazolinone compound containing 1, 2, 4-triazole thioether and synthesizing method and application of quinazolinone compound
Owner:北京传奇优声文化传媒有限公司
6-, 7-, or 8-Substituted Quinazolinone Derivatives and Compositions Comprising and Methods of Using the Same
Provided are quinazolinone compounds, and pharmaceutically acceptable salts, solvates, clathrates, stereoisomers, and prodrugs thereof. Methods of use, and pharmaceutical compositions of these compounds are disclosed.
Owner:CELGENE CORP
Substituted 2-(4-piperidyl)-4(3H)-quinazolinones and 2-(4-piperidyl)-4(3H)-azaquinazolinones
This invention relates to compounds which are generally alpha1A / B-receptor antagonists and which are represented by Formula I:wherein the substituents are as defined in the specification; or pharmaceutically acceptable salts, hydrates, or N-oxides thereof. The invention further relates to pharmaceutical compositions containing such compounds, methods for their use as therapeutic agents, and a process for their preparation.
Owner:SYNTEX (USA) INC
Novel Compositions And Methods Of Treatment
Disclosed inter alia is the use of quinazolinone derivatives, which are modulators of a mitotic kinesin such as KSP, in the treatment of cellular proliferative diseases. The quinazolinone derivatives are administered with another chemotherapeutic agent selected from alkylating agents, antimetabolites, platinating agents, topoisomerase inhibitors, tubulin agents and signalling inhibitors (e.g., kinase inhibitors). Pharmaceutical compositions comprising one or both types of active agents are also disclosed.
Owner:CYTOKINETICS INC
Quinazolinone Compounds and Methods of Use Thereof
The present invention relates to quinazolinone compounds, and methods of preparation of these compounds. The present invention also relates to pharmaceutical compositions comprising the quinazolinone compounds. The present invention provides methods of treating a cell proliferative disorder, such as a cancer, by administering to a subject in need thereof a therapeutically effective amount of a quinazolinone compound of the present invention
Owner:ARQULE INC
Benzoxazinone and quinazolinone derivatives
InactiveUS20040219390A1Organic chemistryDischarge tube luminescnet screensOrganic light emitting deviceBenzoxazinones
Benzoxazinone and quinazolinone compounds useful in organic light emitting devices (OLEDS) are described.
Owner:HONEYWELL INT INC
Method for synthesizing quinazolino indazole derivatives
The invention relates to a method for synthesizing quinazolino indazole derivatives. The method comprises the following steps: using a palladium compound as a catalyst, and producing an intramolecular dehydrogenation coupling reaction of 2-aryl-3-aryl amino quinazolinone derivatives in an oxygen atmosphere in the presence of alkali and a molecular sieve so as to obtain the quinazolino indazole derivatives with diversified structures. The method overcomes the defect that a halogenated compound has to be used as a reaction substrate in the prior art under the synergistic effect of the catalyst, alkali and the molecular sieve, achieves a reaction for efficiently synthesizing the quinazolino indazole derivatives by a one-pot method, has the advantages of high efficiency, environmental friendliness, high yield and purity and the like, expands the application range of the transition metal catalytic dehydrogenation coupling reaction, enriches synthetic methods and paths of the quinazolino indazole derivatives, and has very high theoretical research and application values.
Owner:WENZHOU UNIVERSITY
Substituted quinazoline and quinazolinone compounds and methods of use thereof
Compounds having activity as inhibitors of G12C mutant KRAS protein are provided. The compounds have the following structure (I): (Formula (I)) or a pharmaceutically acceptable salt, stereoisomer thereof, wherein G, Y, R, R1, R2a, R2b, R2c, L, L1 and E are as defined herein. Methods associated with preparation and use of such compounds, pharmaceutical compositions comprising such compounds and methods to modulate the activity of G12C mutant KRAS protein for treatment of disorders, such as cancer, are also provided. Preferred compounds are quinazoline and quinazolinone derivatives and in particular 1-(6-(3-hydroxynaphthalen-1-yl)quinazolin-2-yl)azetidin-1-yl)prop-2-en-1-one derivatives and similar compounds.
Owner:ARAXES PHARMA LLC
Quinazolinones as prolyl hydroxylase inhibitors
Quinazolinone compounds of formula (I) are described,which are useful as prolyl hydroxylase inhibitors. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by prolyl hydroxylase activity. Thus, the compounds may be administered to treat, e.g., anemia, vascular disorders, metabolic disorders, and wound healing.
Owner:JANSSEN PHARMA NV
Quinazolinone KSP inhibitors
Quinazolinones of formulae (a, b, c and d) are disclosed. They are useful for treating cellular proliferative diseases and disorders associated with KSP kinesin activity.
Owner:CYTOKINETICS INC
Substituted isoquinolinones and quinazolinones
ActiveUS20130281473A1Good metabolic stabilityProlong half-life in vivoOrganic active ingredientsBiocideChemistryQuinazolinone
Owner:NOVARTIS AG
Substituted quinazolinone compounds
Owner:CHIRON CORP
Pyrrolo[2,1-C][1,4]benzodiazepine hybrids and a process for the preparation thereof
The present invention provides quinazolinone linked pyrrolo[2,1-c][1,4]benzodiazepine hybrid of general formula 5,wherein, R is alkyl or halo group selected from H, Cl, F or CH3 and n=1 to 3 useful for antitumour / anticancer activity. The present invention also provides a process for the preparation of quinazolinone linked pyrrolo[2,1-c][1,4]benzodiazepine hybrid general formula 5.
![Pyrrolo[2,1-C][1,4]benzodiazepine hybrids and a process for the preparation thereof](https://images-eureka.patsnap.com/patent_img/09c9b3a1-3f78-4dd2-85e4-c8d6f270e0ed/US07608615-20091027-D00001.png "Pyrrolo[2,1-C][1,4]benzodiazepine hybrids and a process for the preparation thereof")
![Pyrrolo[2,1-C][1,4]benzodiazepine hybrids and a process for the preparation thereof](https://images-eureka.patsnap.com/patent_img/09c9b3a1-3f78-4dd2-85e4-c8d6f270e0ed/US07608615-20091027-C00001.png "Pyrrolo[2,1-C][1,4]benzodiazepine hybrids and a process for the preparation thereof")
![Pyrrolo[2,1-C][1,4]benzodiazepine hybrids and a process for the preparation thereof](https://images-eureka.patsnap.com/patent_img/09c9b3a1-3f78-4dd2-85e4-c8d6f270e0ed/US07608615-20091027-C00002.png "Pyrrolo[2,1-C][1,4]benzodiazepine hybrids and a process for the preparation thereof")
Owner:COUNCIL OF SCI & IND RES
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com